Literature DB >> 10988282

Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients.

P R Conlin1, T J Moore, S L Swartz, E Barr, L Gazdick, C Fletcher, P DeLucca, L Demopoulos.   

Abstract

NSAIDs are known to attenuate the effects of some antihypertensive medications. It is not known whether the new class of angiotensin II receptor antagonists is similarly affected. We conducted a multicenter study assessing the effect of indomethacin on the antihypertensive effects of losartan and captopril. After 4 weeks of placebo washout, hypertensive patients received 6 weeks of active antihypertensive therapy with either 50 mg losartan once daily (n=111) or 25 mg captopril twice daily for 1 week, which was increased to 50 mg twice daily for 5 weeks (n=105). This was followed by 1 week of concomitant therapy with indomethacin (75 mg daily). The primary outcome measure was the change in mean 24-hour ambulatory diastolic blood pressure after the addition of indomethacin. Both captopril and losartan significantly lowered ambulatory diastolic blood pressure (losartan -5.3 mm Hg, P:<0.001; captopril -5.6 mm Hg, P:<0.001) after 6 weeks of therapy. Indomethacin significantly attenuated the 24-hour ambulatory diastolic blood pressure for both losartan (2.2 mm Hg, P:<0.05) and captopril (2.7 mm Hg, P:<0.001) and also attenuated the effect of captopril on trough sitting diastolic blood pressure. Changes in daytime diastolic blood pressure (7:00 AM to 11:00 PM) were similar to the 24-hour response in both groups. Nighttime diastolic blood pressure (11:01 PM to 6:59 AM) was significantly attenuated in captopril-treated patients (2.0 mm Hg, P:<0.05), but losartan was unaffected (0.4 mm Hg). Thus, concurrent treatment with indomethacin similarly attenuates the 24-hour antihypertensive response to losartan and captopril.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10988282     DOI: 10.1161/01.hyp.36.3.461

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

1.  Drug-induced causes of secondary hypertension.

Authors:  Wilbert S Aronow
Journal:  Ann Transl Med       Date:  2017-09

Review 2.  A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects.

Authors:  Emma J Turtle; James W Dear; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

3.  Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study.

Authors:  Jean-Pascal Fournier; Agnès Sommet; Robert Bourrel; Stéphane Oustric; Atul Pathak; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2012-04-15       Impact factor: 2.953

Review 4.  Management of Hypertension in Patients with Chronic Kidney Disease.

Authors:  Seyed Mehrdad Hamrahian
Journal:  Curr Hypertens Rep       Date:  2017-05       Impact factor: 5.369

5.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 6.  Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives.

Authors:  Thomas Unger; Elena Kaschina
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents.

Authors:  T M MacDonald; D Richard; K Lheritier; G Krammer
Journal:  Int J Clin Pract       Date:  2010-05       Impact factor: 2.503

8.  A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension.

Authors:  Chrisa Dimou; Christina Antza; Evangelos Akrivos; Ioannis Doundoulakis; Stella Stabouli; Anna Bettina Haidich; Vasilios Kotsis
Journal:  J Hum Hypertens       Date:  2018-12-05       Impact factor: 3.012

Review 9.  Resistant or difficult-to-treat hypertension.

Authors:  David A Calhoun
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-03       Impact factor: 3.738

Review 10.  Beyond the usual strategies for blood pressure reduction: therapeutic considerations and combination therapies.

Authors:  T D Giles; G E Sander
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Nov-Dec       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.